Can Trastuzumab be used in combination with Pertuzumab?

Trastuzumab and Pertuzumab are two targeted drugs commonly used to treat HER2-positive breast cancer. They can often be used together to form combination treatments to improve efficacy. The combined use of trastuzumab and pertuzumab can simultaneously target HER2 through different mechanisms and exert a synergistic effect. This combination treatment regimen has been shown to have significant clinical benefit in the treatment of HER2-positive breast cancer.

Compared with trastuzumab monotherapy, combination therapy significantly improved late-stage and neoadjuvant treatment outcomes in patients with HER2-positive breast cancer and was well tolerated, with no increase in total grade ≥3 adverse reactions and serious adverse events. However, in Asian patients, the incidence of overall grade ≥3 adverse reactions and serious adverse events was higher in the dual therapy group, which requires closer monitoring in clinical practice. Recommendations for pertuzumab, trastuzumab, and T-DM1 for their use in patients with pre-treatment LVEF exceeding 50% or 55% suggest dose delay or discontinuation if left ventricular ejection fraction (LVEF) decreases during treatment.

Trastuzumab is sold under the brand name Herceptin in China and has entered the scope of Class B medical insurance, but it may be limited to patients who meet the indications for this drug, such as patients with HER2-positive metastatic breast cancer and its adjuvant and neoadjuvant treatment or HER2-positive metastatic gastric cancer. The price is around 6,000 yuan. The original trastuzumab drug has also been launched overseas. The drug ingredients of domestic and foreign original drugs are basically the same. For specific prices and drug details, you can consult the medical consultant. There is currently no generic drug of trastuzumab on the market.